Leong L Ng1, Jatinderpal K Sandhu2, Hafid Narayan2, Paulene A Quinn2, Iain B Squire2, Joan E Davies2, Andreas Bergmann3, Alan Maisel4, Donald J L Jones5. 1. Department of Cardiovascular Sciences and National Institute for Health Research, Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, United Kingdom. Electronic address: lln1@le.ac.uk. 2. Department of Cardiovascular Sciences and National Institute for Health Research, Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, United Kingdom. 3. Department of Cancer Studies and Molecular Medicine, Leicester Royal Infirmary, University of Leicester, Leicester, United Kingdom. 4. San Diego VA Medical Center, San Diego, California. 5. Sphingotec GmbH, Hennigsdorf, Germany.
Abstract
OBJECTIVES: The goal of this research was to assess the prognostic value of proenkephalin (PENK) levels in acute myocardial infarction (AMI) by using N-terminal pro-B-type natriuretic peptide and Global Registry of Acute Coronary Events (GRACE) scores as comparators and to identify levels that might be valuable in clinical decision making. BACKGROUND: PENK is a stable analyte of labile enkephalins. Few biomarkers predict recurrent AMI. METHODS: We measured PENK in 1,141 patients (820 male subjects; mean age 66.2 ± 12.8 years) with AMI. Endpoints were major adverse events (composite of death, myocardial infarction [MI], and heart failure [HF] hospitalization) and recurrent MI at 2 years. GRACE scoring was used for comparisons with PENK for the death and/or MI endpoint at 6 months. RESULTS: During follow-up, 139 patients died, and there were 112 HF hospitalizations and 149 recurrent AMIs. PENK levels were highest on admission and were related to estimated glomerular filtration rate, left ventricular wall motion index, sex, blood pressure, and age. Multivariable Cox regression models found that the PENK level was a predictor of major adverse events (hazard ratio [HR]: 1.52 [95% confidence interval (CI): 1.19 to 1.94]), death and/or AMI (HR: 1.76 [95% CI: 1.34 to 2.30]), and death and/or HF (HR: 1.67 [95% CI: 1.24 to 2.25]) (all comparisons p < 0.001), as well as recurrent AMI (HR: 1.43 [95% CI: 1.07 to 1.91]; p < 0.01). PENK levels were independent predictors of 6-month death and/or MI compared with GRACE scores. PENK-adjusted GRACE scores reclassified patients significantly (overall category-free net reclassification improvement [>0] of 21.9 [95% CI: 4.5 to 39.4]; p < 0.014). PENK levels <48.3 pmol/l and >91 pmol/l detected low- and high-risk patients, respectively. CONCLUSIONS: PENK levels reflect cardiorenal status post-AMI and are prognostic for death, recurrent AMI, or HF. Cutoff values define low- and high-risk groups and improve risk prediction of GRACE scores.
OBJECTIVES: The goal of this research was to assess the prognostic value of proenkephalin (PENK) levels in acute myocardial infarction (AMI) by using N-terminal pro-B-type natriuretic peptide and Global Registry of Acute Coronary Events (GRACE) scores as comparators and to identify levels that might be valuable in clinical decision making. BACKGROUND:PENK is a stable analyte of labile enkephalins. Few biomarkers predict recurrent AMI. METHODS: We measured PENK in 1,141 patients (820 male subjects; mean age 66.2 ± 12.8 years) with AMI. Endpoints were major adverse events (composite of death, myocardial infarction [MI], and heart failure [HF] hospitalization) and recurrent MI at 2 years. GRACE scoring was used for comparisons with PENK for the death and/or MI endpoint at 6 months. RESULTS: During follow-up, 139 patients died, and there were 112 HF hospitalizations and 149 recurrent AMIs. PENK levels were highest on admission and were related to estimated glomerular filtration rate, left ventricular wall motion index, sex, blood pressure, and age. Multivariable Cox regression models found that the PENK level was a predictor of major adverse events (hazard ratio [HR]: 1.52 [95% confidence interval (CI): 1.19 to 1.94]), death and/or AMI (HR: 1.76 [95% CI: 1.34 to 2.30]), and death and/or HF (HR: 1.67 [95% CI: 1.24 to 2.25]) (all comparisons p < 0.001), as well as recurrent AMI (HR: 1.43 [95% CI: 1.07 to 1.91]; p < 0.01). PENK levels were independent predictors of 6-month death and/or MI compared with GRACE scores. PENK-adjusted GRACE scores reclassified patients significantly (overall category-free net reclassification improvement [>0] of 21.9 [95% CI: 4.5 to 39.4]; p < 0.014). PENK levels <48.3 pmol/l and >91 pmol/l detected low- and high-risk patients, respectively. CONCLUSIONS:PENK levels reflect cardiorenal status post-AMI and are prognostic for death, recurrent AMI, or HF. Cutoff values define low- and high-risk groups and improve risk prediction of GRACE scores.
Authors: Christina-Alexandra Schulz; Anders Christensson; Ulrika Ericson; Peter Almgren; George Hindy; Peter M Nilsson; Joachim Struck; Andreas Bergmann; Olle Melander; Marju Orho-Melander Journal: J Am Soc Nephrol Date: 2016-07-08 Impact factor: 10.121
Authors: Rossella Marino; Joachim Struck; Oliver Hartmann; Alan S Maisel; Miriam Rehfeldt; Laura Magrini; Olle Melander; Andreas Bergmann; Salvatore Di Somma Journal: J Nephrol Date: 2014-12-09 Impact factor: 3.902
Authors: Christopher Nilsson; Anders Christensson; Peter M Nilsson; Olle Melander; Louise Bennet Journal: Scand J Clin Lab Invest Date: 2021-09-28 Impact factor: 1.713
Authors: Lyanne M Kieneker; Oliver Hartmann; Joachim Struck; Andreas Bergmann; Ron T Gansevoort; Michel M Joosten; Else van den Berg; Rudolf A de Boer; Stephan J L Bakker Journal: Transplant Direct Date: 2017-07-07
Authors: Hanah Kim; Mina Hur; Seungho Lee; Rossella Marino; Laura Magrini; Patrizia Cardelli; Joachim Struck; Andreas Bergmann; Oliver Hartmann; Salvatore Di Somma Journal: Ann Lab Med Date: 2017-09 Impact factor: 3.464
Authors: Jana C Mossanen; Jessica Pracht; Tobias U Jansen; Lukas Buendgens; Christian Stoppe; Andreas Goetzenich; Joachim Struck; Rüdiger Autschbach; Gernot Marx; Frank Tacke Journal: Int J Mol Sci Date: 2017-07-31 Impact factor: 5.923
Authors: Jiang Xie; Fatima H Sert Kuniyoshi; Naima Covassin; Prachi Singh; Apoor S Gami; C Anwar A Chahal; Virend K Somers Journal: J Am Heart Assoc Date: 2018-01-19 Impact factor: 5.501
Authors: Kornelis J J van Hateren; Gijs W D Landman; Jarinke F H Arnold; Hanneke Joosten; Klaas H Groenier; Gerjan J Navis; Andrea Sparwasser; Stephan J L Bakker; Henk J G Bilo; Nanne Kleefstra Journal: PLoS One Date: 2015-07-28 Impact factor: 3.240
Authors: Jiang Xie; Fatima H Sert Kuniyoshi; Naima Covassin; Prachi Singh; Apoor S Gami; Shihan Wang; C Anwar A Chahal; Yongxiang Wei; Virend K Somers Journal: J Am Heart Assoc Date: 2016-07-27 Impact factor: 5.501